Summary:
This UK SME will be launching their new treatment for wounds that combines multiple actions to tackle problem wounds in a single product that fits existing dressing reimbursement categories. They are looking for a dynamic and highly ethical wound care distributor to work with them on a focused launch and grow the business in the US market. This will be via a distribution services agreement.
Description:
The product is a treatment in the form of a gelling fiber dressing. It disrupts bacterial and yeast (candida) biofilms, has a long-lasting antimicrobial effect and at the same time is highly absorbent for treating highly exuding wounds. It outperforms leading silver dressings in tests on fibroblast cells, showing significantly reduced local toxicity, creating a unique combination. The company are working with respected independent labs and universities on these tests to build a strong research base for the product.
The active component is an iodophor (iodine compound). Iodophors have been identified as the most effective agents tested against biofilms in wounds. They have filed several patents covering the technology. The dressing is manufactured in a range of sizes, to match the existing widely-used dressings in this field.
The company are a small UK based, dedicated to wound care and founded on expertise from long experience in blue chip companies in the field. They are looking to partner with US distributers via a distribution services agreeement
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
The company are small UK based, dedicated to wound care and founded on expertise from long experience in blue chip companies in this field of health care.
They are looking to partner with US distributers who have experience and have a portfolio of products that would be complimentary to this product and could add vaue. This is envisiaged to be via a distribution services agreement
Stage of Development:
Available for demonstration
Comments Regarding Stage of Development:
The dressing is designed and in late development, at the stage of assembling the dossier to submit this calendar year for FDA approval. They have had independent laboratory studies carried out on the performance to confirm the properties. The product is classified as a dressing. Research studies to support the unique properties have been accepted for conference presentation and they are building on these publications for launch.
IPR Status:
Patent(s) applied for but not yet granted
External code:
BOUK20211220001
